The DOI matches its Crossref record; 327 of the 327 references it cites were found in a registry or an index; 135 of the 655 sources its claims cite were checked for support.
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Open accessAbstract
Type 2 diabetes (T2D), which has currently become a global pandemic, is a metabolic disease largely characterised by impaired insulin secretion and action. Significant progress has been made in understanding T2D aetiology and pathogenesis, which is discussed in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone responsible for augmenting insulin secretion from pancreatic beta-cells during the postprandial period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much longer half-life have been developed, which are currently an effective treatment option for T2D by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, these therapies have been shown to induce weight loss in patients, suggesting they could be an alternative to bariatric surgery, a procedure associated with numerous complications. Current GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have been developed for these sites to test their therapeutic potential. Recent studies have also demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R mechanisms of activation via different agonists, will likely provide better insight into the therapeutic potential of GLP-1-based therapies to treat T2D.
Overview
CoChat Summary
TL;DR
This narrative review summarizes type 2 diabetes epidemiology, multifactorial aetiology/pathogenesis, extrapancreatic complications, and treatments, with emphasis on GLP-1 receptor-based therapies. It argues that GLP-1R agonists, including emerging allosteric and multi-receptor agonists, may improve glycaemia, weight, and systemic complications, while many mechanistic uncertainties remain.
Key findings
- T2D is described as a global pandemic: ~382 million patients globally in 2013, projected >590 million by 2035 and >700 million by 2045; T2D accounts for ~90% of diabetes cases. Obesity is a major risk factor, reported to increase T2D risk by 90-fold, and genetic susceptibility is supported by ~70% monozygotic twin concordance, 40% lifetime risk with one affected parent, and almost 70% with both parents affected.
- Pathogenesis involves beta-cell dysfunction/apoptosis, peripheral insulin resistance, alpha-cell dysregulation, islet amyloid/IAPP deposition, and a diminished incretin effect, where GLP-1 and GIP account for <20% of insulin release after glucose ingestion in T2D. Extrapancreatic pathology includes cardiovascular disease, diabetic nephropathy, neuropathy, and NAFLD, reported in ~70% of T2D patients.
- GLP-1-based therapies are central: native GLP-1 has a half-life of 1–2 minutes, whereas exenatide has 3.4–4 hours and liraglutide 11–13 hours; GLP-1R agonists augment glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and induce weight loss. In a 160-week liraglutide trial, T2D diagnosis occurred in 2% vs 6% of placebo-treated participants, and time to T2D onset was 2.7x longer with liraglutide.
- Emerging approaches include GLP-1R allosteric agonists (compounds 2 and B) and GLP-1/GIP/glucagon tri-agonists tested in rodents, which improved glycaemia, body weight, and islet architecture. Bariatric surgery can induce T2D remission—one study reported 53% complete remission at three years and another 10% partial remission—but carries complications such as vomiting/dumping syndrome, iron and B12 deficiency, and secondary hyperparathyroidism.
Methods
- Narrative review of published literature on T2D epidemiology, aetiology, pathogenesis, treatments, and future perspectives; no primary data collection or systematic search strategy is described.
- Synthesizes preclinical and clinical evidence, including rodent models, human islets, autopsy studies, and clinical trials; the main analysis is qualitative narrative synthesis.
Limitations
- The paper does not present a formal limitations section; limitations stated in the text include unresolved mechanisms, conflicting findings (e.g., glucolipotoxicity, UCP2, GIP action), uncertainty from undiagnosed diabetes in global prevalence estimates, and the caveat that animal-study observations may have limited clinical implications for humans.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal quality appraisal, and it relies on heterogeneous cited studies without meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
87 Valid · 11 Not valid · 355 Not checked · 7 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study demonstrated the importance of genetics in T2D susceptibility independently of the diet as there was a higher prevalence of the disease in the twin population compared to the singleton population77”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Aetiology
What the sources say
- Disputedcites [77] Poulsen, 2009, Diabetes sourceExperimental — accuracy not yet measured
The Discussion confirms that elderly twins had a higher prevalence of type 2 diabetes than singletons. But the Abstract’s Conclusions interpret the finding as evidence for a significant impact of the fetal environment “as opposed to genetics,” contrary to the claim that the comparison demonstrates the importance of genetics. These passages also do not establish independence from diet. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“It has been shown that a high proton motive force (PMF) results in the production of ROS, and as UCP2 activity can lower the PMF by increasing proton leak, it can then lower intracellular ROS, as well as increased production of ROS, is thought to be at least partly dependent on an increased mitochondrial PMF in islet beta-cells.180,183–185”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
What the sources say
- Supportedcites [180] Affourtit, 2011, Free Radic Biol Med source
The Discussion (‘UCP2 function and regulation’) says UCP2 contributes to mitochondrial proton leak. The Discussion (‘GSIS regulation by UCP2’) also describes UCP2 activity as partially dissipating mitochondrial membrane potential, supporting the claimed mechanism. (LLM, conf=0.92)
- Not checked yetcites [183] Pi, 2010, Diabetes Obes Metab source
- Disputedcites [184] Robson-Doucette, 2011, Diabetes sourceExperimental — accuracy not yet measured
The paper’s Results say UCP2 does not contribute to classical proton leak in β-cells, and its Discussion says the increased ROS observed after UCP2 deletion is not caused by reduced proton leak. Although the introduction acknowledges reports of UCP2-facilitated proton leak elsewhere, the paper’s findings contradict that mechanism in the islet β-cell context of the citing sentence. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“TNFα secretion from T2D subjects was higher than healthy controls,207,208 and one in vitro study has shown that this myokine impairs beta-cell function.208”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Extrapancreatic Tissues Involvement in T2D: Aetiology/Pathogenesis and Post-Diagnosis Complications
What the sources say
- Supportedcites [207] Ciaraldi, 2016, PLoS One source
The Results/Discussion of our copy state that TNFa secretion is elevated in T2D myotubes relative to non-diabetic cells: Discussion (p. n/a) says 'Our current observation that TNFa secretion, while low, is elevated in T2D myotubes is confirmatory of our earlier results', and the Discussion also summarizes 'our results that secretion of TNFa, IL6 and MCP-1 are all elevated in T2D myotubes'. The Introduction frames the same comparison against cells from non-diabetic (ND) individuals. Note the parallel circulating TNFa difference in Table 2 was not retained after BMI adjustment, but the claim concerns secretion, which the paper supports. (LLM, conf=0.90)
- Disputedcites [208] Bouzakri, 2011, Diabetes sourceExperimental — accuracy not yet measured
Our copy contains no measurement of TNF-α secretion comparing type 2 diabetic subjects with healthy controls; the study is entirely in vitro, using human myotubes rendered insulin resistant by added TNF-α (RESULTS, 'Myokine expression and secretion from human skeletal muscle cells (myotubes) treated with or without TNF-α'). On the contrary point, the DISCUSSION states 'At present, there is little evidence for elevated TNF-α in the skeletal muscle of individuals with type 2 diabetes,' and the background passage (labeled Abstract > CONCLUSIONS in our copy) says the source of increased circulating TNF-α in type 2 diabetes 'remains unclear, but it does not appear to be the muscle itself (18),' with elevated levels in obesity/T2D credited to refs 18-19 rather than shown here. So the muscle-derived ('myokine') elevation the citing sentence attributes to this source is contradicted by our copy; only the separate in vitro β-cell/GSIS impairment finding (TNF-α in TM blunting GSIS, blocked by Ethanercept) is supported. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are a range of effective treatments that reduce hyperglycaemia in T2D patients, which mediate their effects by improving insulin secretion or decreasing peripheral tissue insulin resistance.8”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [8] Raz, 2013, Diabetes Care source
The paper’s sections on individual drug classes describe several effective glucose-lowering treatments with these mechanisms. The sulfonylureas and meglitinides section says they increase insulin secretion, while the PPAR-γ: pioglitazone section says that class lowers blood glucose by reducing insulin resistance and improving insulin sensitivity in muscle. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [11] Horton, 2010, Diabetes Care source
The Conclusions report that weight loss was associated with better glycemic control in patients with type 2 diabetes. The Results (Regression analysis) specify that this benefit appeared with any weight loss in exenatide-treated patients, but only with weight loss of at least 8% in the sitagliptin and insulin groups. (LLM, conf=0.92)
- Supportedcites [12] Wilding, 2014, Int J Clin Pract source
The ‘Effects on glycaemic control’ section says that weight loss improves glycaemic control in people with T2DM and that those who lose weight are more likely to reach target HbA1c values. The ‘Message for the clinic’ and Introduction also link excess weight to cardiometabolic complications and cardiovascular risk. Page numbers are not available in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
212 more claims · 48 with their cited sources checked
Create a free account to see all 460 claims and to verify the 520 references still open.
- It may state two separate claims as one. 213
- Probably not a substantial claim. 60
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence supports the concept that deposition of ectopic fat within pancreatic islets, possibly inside β cells themselves, contributes to progressive impairment of β-cell function (which is reversible with weight loss)115 in individuals who are genetically susceptible.116–118”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“peripheral insulin resistance is a requisite precursor for the development of this disease.”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“T2D has been shown to manifest in non-overweight individuals in the absence of insulin resistance, although this is thought to be rare.140”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“exenatide has a half-life of 3.4–4 hours”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“| Exenatide (Byetta) | Twice daily | 2.4 hours | Yes |”
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 6×
“estimated that there will be over 700 million T2D patients worldwide.(1,62) However, as highlighted in”
InfluentialBiochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Research works printed but not linked: 25
- Thompson, 2013, Clin Exp Pharmacol, 1, 3
- 2010, Clinical Problems Caused by Obesity
- 2012, The Disease Burden Associated with Overweight and Obesity
- Templeman, 2017, J Endocrinol, 2017, 58
- Hu, 2011, Role Diet Lifestyle Genes, 34, 1249
- 2011, Biochemistry
- Karalliedde, 2016, Nephrol Dialysis Transplant, 31, 206
- Ali, 2010, Indian J Med Res, 132, 584
- Mazzola, 2012, Am J Manag Care, 18, 17
- Saeedi, 2019, Diabetes Res Clin Pract, 2, 157
- 1985, Diabetes in America
- Hyttinen, 2003, Nationwide Follow Up Study, 52, 1052
- Torres, 2008, Gastroenterol Hepatol (N Y), 4, 568
- Wilcox, 2005, Clin Biochemist Rev, 26, 19
- Cnop, 2005, Many Differences Few Similarities, 54, S97
- Gerich, 2000, J Clin Endocrinol Metab, 85, 2113
- Ivan Quesada, 2008, J Endocrinol, 2, 68
- Shah, 2000, J Clin Endocrinol Metab, 85, 4053
- Clark, 1988, Diabetes Res, 9, 151
- Perry, 2016, Exerc Immunol Rev, 22, 94
- Keshel, 2015, J Obes Weight Loss Ther, 5, S5
- 2018, Encyclopedia of Signaling Molecules
- Halverson, 1986, Am Surg, 52, 594
- Avinoah, 1992, Surgery, 111, 137
- 2017, Encyclopedia of Signaling Molecules
Cited by
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Dietary Polyphenols as Natural Inhibitors of α-Amylase and α-Glucosidase
Ćorković, I., Gašo-Sokač, D., Pichler, A., Šimunović, J., & Kopjar, M. (2022) · Life · doi:10.3390/life12111692 · Cited by 208
“Various socioeconomic and cultural aspects cause overweight and obesity, which are consequently leading to increased risk for the disease’s development [1,2].”
BackgroundSingh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
Anh, N. H., Mai, Q. D., Dinh, N. X., Huy, T. Q., Tri, D. Q., Loan, L. T. N., Bui, H. V., & Le, A.-T. (2022) · RSC Advances · doi:10.1039/d1ra08311b · Cited by 100
Varney, M. J., & Benovic, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001015 · Cited by 88
“In T2D, b -cell dysfunction and peripheral insulin resistance create an environment that limits glucose uptake in muscle and adipose and increases hepatic glucose production, causing and exacerbating hyper-glycemia (Kahn et al., 2014; Reed et al., 2021).”
BackgroundInfluentialComan, L.-I., Ianculescu, M., Paraschiv, E.-A., Alexandru, A., & Bădărău, I.-A. (2024) · Applied Sciences · doi:10.3390/app14062351 · Cited by 99
D-Pinitol—Active Natural Product from Carob with Notable Insulin Regulation
Azab, A. (2022) · Nutrients · doi:10.3390/nu14071453 · Cited by 62
“Type 2 diabetes (T2D) is defined by the World Health Organization (WHO) as a “metabolic disorder of multiple etiology characterized by chronic hyperglycemia with disturbance of carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action, or both” [17].”
BackgroundCai, X., Zhu, Q., Liu, S., Wang, M., Wu, T., Hong, J., Hu, J., & Li, N. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s336990 · Cited by 70
“It is predicted to increase to 7079 per 100,000 people by 2030, reflecting a continued rising and showing no signs of stabilization worldwide.(3,4) To Correspondence: Nanfang Li Graduate School, Xinjiang Medical University; Hypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hyperten…”
BackgroundPandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 68
Alwadeai, K. S., & Alhammad, S. A. (2023) · Medicine · doi:10.1097/md.0000000000034021 · Cited by 63
“Type 2 diabetes mellitus (T2DM) is one of the world’s most prevalent chronic metabolic diseases with high blood glucose levels.[1,2] Adipokines have been linked in a recent study to the etiology of obesity and the elevated risk of several comorbidities, particularly T2DM.”
BackgroundGriebsch, L. V., Theiss, E. L., Janitschke, D., Erhardt, V. K. J., Erhardt, T., Haas, E. C., Kuppler, K. N., Radermacher, J., Walzer, O., Lauer, A. A., et al. (2023) · Nutrients · doi:10.3390/nu15061467 · Cited by 68
“In recent decades, the medical and socio-economic interest in non-nutritive and synthetic sweeteners has risen due to a worldwide increase in obesity and metabolic diseases such as type 2 diabetes, among other things [1,2].”
BackgroundJiang, S., Liu, A., Ma, W., Liu, X., Luo, P., Zhan, M., Zhou, X., Chen, L., & Zhang, J. (2023) · Food & Function · doi:10.1039/d3fo01701j · Cited by 57
Epigenetics and Beyond: Targeting Histone Methylation to Treat Type 2 Diabetes Mellitus
Yang, Y., Luan, Y., Feng, Q., Chen, X., Qin, B., Ren, K., & Luan, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807413 · Cited by 59
“This disease serves as a high-prevalence epidemic that currently affects approximately 316 million people, which is estimated to reach 470 million by the year 2035 (Reed et al., 2021).”
BackgroundWu, Y., Shen, G., & Hao, C. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.20230386 · Cited by 47
Cong, Z., Zhou, Q., Li, Y., Chen, L.-N., Zhang, Z.-C., Liang, A., Liu, Q., Wu, X., Dai, A., Xia, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200155119 · Cited by 43
Zhang, X., Wang, X., Wang, M., Hu, B., Tang, W. F., Wu, Y., Gu, J., Tian, N., & Li, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.966093 · Cited by 44
Diabetic Foot Ulcer in India: Aetiological Trends and Bacterial Diversity
Kale, D., Karande, G., & Datkhile, K. D. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_458_22 · Cited by 48
Capsaicin, its clinical significance in patients with painful diabetic neuropathy
Dludla, P. V., Nkambule, B. B., Cirilli, I., Marcheggiani, F., Mabhida, S. E., Ziqubu, K., Ntamo, Y., Jack, B. U., Nyambuya, T. M., Hanser, S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113439 · Cited by 40
Deledda, A., Palmas, V., Heidrich, V., Fosci, M., Lombardo, M., Cambarau, G., Lai, A., Melis, M., Loi, E., Loviselli, A., et al. (2022) · Metabolites · doi:10.3390/metabo12111092 · Cited by 55
“Furthermore, MD also has a positive impact on pollution and environmental sustainability, and these features also contribute to reducing the risk of CVD and promoting overall wellness [57,58].”
BackgroundMolecular Genetics of Abnormal Redox Homeostasis in Type 2 Diabetes Mellitus
Azarova, I. E., Polonikov, A., & Klyosova, E. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054738 · Cited by 40
Mitochondrial Dysfunction as a Factor of Energy Metabolism Disorders in Type 2 Diabetes Mellitus
Blagov, A. V., Nedosugova, L., Kirichenko, T. V., Sukhorukov, V. N., Melnichenko, A. А., & Orekhov, A. N. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1601005 · Cited by 45
“The World Health Organization (WHO) defines diabetes as “a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia with impaired carbohydrate, fat, and protein metabolism as a result of defects in insulin se-cretion” [ 2].”
Kukułowicz, J., Pietrzak-Lichwa, K. J., Klimończyk, K., Idlin, N., & Bajda, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000886 · Cited by 37
Cardozo-Muñoz, J., Suárez, L. E. C., Prieto-Rodríguez, J. A., López-Vallejo, F., & Patiño-Ladino, O. J. (2022) · Molecules · doi:10.3390/molecules27103283 · Cited by 32
“However, many of these products have been associated with some gastrointestinal problems including bloating, diarrhea, flatulence, and abdominal discomfort [8,11,15].”
BackgroundLo, C. H., O’Connor, L. M., Loi, G. W. Z., Saipuljumri, E. N., Indajang, J., Lopes, K. M., Shirihai, O. S., Grinstaff, M. W., & Zeng, J. (2024) · ACS Nano · doi:10.1021/acsnano.3c09206 · Cited by 36
Jafari, A., Naddafi, F., Gholian‐Aval, M., & Tehrani, H. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01391-z · Cited by 42
“Type 2 diabetes (T2D) is the global challenge of the 21st century and the most common metabolic disease [1, 2].”
BackgroundEl‐Askary, H. I., Salem, H. H., & Motaal, A. A. A. (2022) · Molecules · doi:10.3390/molecules27030857 · Cited by 32
“Diabetes mellitus is a chronic metabolic disorder defined by elevated blood glucose level due to defective insulin secretion [1].”
BackgroundShaikh, S., Ali, S. M., Lim, J. H., Chun, H. J., Ahmad, K., Ahmad, S. S., Hwang, Y. C., Han, K. S., Kim, N., Lee, E. J., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1024764 · Cited by 37
“Moreover, diabetes has been reported to be responsible for around 10% of all fatalities (Reed et al., 2021).”
BackgroundEpigenetic regulatory mechanism of macrophage polarization in diabetic wound healing (Review)
Song, J., Wu, Y., Chen, Y., Sun, X., & Zhang, Z. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13367 · Cited by 38
Natural Compounds for Preventing Age-Related Diseases and Cancers
Ki, M., Youn, S., Kim, D. H., & Pack, S. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147530 · Cited by 32
Tienda-Vázquez, M. A., Melchor-Martínez, E. M., Elizondo‐Luévano, J. H., Parra‐Saldívar, R., Lara-Ortiz, J. S., Luna-Sosa, B., & Scheckhuber, C. Q. (2023) · Processes · doi:10.3390/pr11051299 · Cited by 29
Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., Bristow, T. C., Heng, J., Gupta, A., Ovenden, C., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.16126 · Cited by 26
Insulin resistance and cancer: molecular links and clinical perspectives
Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Gemelli, M. T., Ricotta, R., Sasso, F. C., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05245-8 · Cited by 29
“Studies have demonstrated that individuals with T2DM are 10–20% more likely to develop cancer compared to the general population, the risk varying depending on the type of cancer and geographic region [5].”
New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
Jarosinski, M. A., Chen, Y., Varas, N., Dhayalan, B., Chatterjee, D., & Weiss, M. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab849 · Cited by 26
“These include metformin as a first-line agent with subsequent addition of one of several classes (DPP4 inhibitors, sulfonylureas, GLP-1 receptor agonists, or SGLT2 inhibitors) (21-24).”
BackgroundTvrdá, E., Kováč, J., Ferenczyová, K., Kaločayová, B., Ďuračka, M., Benko, F., Almášiová, V., & Barteková, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416056 · Cited by 27
“[3] suggests that obese individuals are up”
BackgroundInsulitis in human type 1 diabetes: lessons from an enigmatic lesion
Morgan, N. G. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae002 · Cited by 24
Xu, N., Wan, J., Wang, C., Liu, J., Qian, C., & Tan, H. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s370206 · Cited by 22
“Introduction Type 2 diabetes mellitus (DM) is one of the most common severe public health problems in the 21st century globally.(1) China has the highest number of Type 2 diabetes mellitus (T2DM) patients, accounting for over 90% of all diabetes mellitus patients locally.”
BackgroundEsquivel-Hernandez, D. A., Martínez-López, Y. E., Sánchez-Castañeda, J. P., Neri-Rosario, D., Padrón-Manrique, C., Giron-Villalobos, D., Mendoza-Ortíz, C., & Reséndis-Antonio, O. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1128767 · Cited by 24
Aboismaiel, M. G., Amin, M. N., & Eissa, L. A. (2024) · Biological Research · doi:10.1186/s40659-024-00527-9 · Cited by 33
“The prevalence of DN is increasing in tandem with the rising prevalence of diabetes mellitus particularly type 2 diabetes mellitus which accounts for about 90% of patients with diabetes [2].”
BackgroundMoreira, R., Martins, A. D., Alves, M. G., Pereira, M. D. L., & Oliveira, P. F. (2023) · Antioxidants · doi:10.3390/antiox12081572 · Cited by 25
“When untreated, it leads to hyperglycemia, dyslipidemia, insufficient amino acid uptake, and ATP production [46] Regarding its antidiabetic effects, CrPic3 is capable of: (1) increasing insulin sensitivity [47,48], (2) increasing glucose tolerance and uptake (both basal and insulinstimulated) [45,49], and (3) preventi…”
BackgroundGhasemi, P., Jafari, M., Jafari-Maskouni, S., Hosseini, S. A., Amiri, R., Hejazi, J., Chambari, M., Tavasolian, R., & Rahimlou, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00824-w · Cited by 24
“Notably, T2DM accounts for approximately 90–95% of these cases [2].”
BackgroundMethodInfluentialFaizan, M., Sarkar, A., & Singh, M. P. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101727 · Cited by 25
Ankit, P., Chong, K. T., & Tayara, H. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106406 · Cited by 20
Growing importance of urogenital candidiasis in individuals with diabetes: A narrative review
Talapko, J., Meštrović, T., & Škrlec, I. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i10.809 · Cited by 27
Odimegwu, C. L., Uwaezuoke, S. N., Chikani, U. N., Mbanefo, N. R., Adiele, K., Nwolisa, C. E., Eneh, C. I., Ndiokwelu, C. O., Okpala, S. C., Ogbuka, F. N., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s479077 · Cited by 26
Atas, E., Berchtold, K., Schlederer, M., Prodinger, S., Sternberg, F., Pucci, P., Steel, C., Matthews, J. D., James, E. R., Philippe, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02320-y · Cited by 22
Endothelial progenitor cells as biomarkers of diabetes-related cardiovascular complications
Benítez-Camacho, J., Ballesteros, A., Beltrán-Camacho, L., Rojas-Torres, M., Rosal‐Vela, A., Jiménez-Palomares, M., Sánchez-Gomar, I., & Durán-Ruiz, M. C. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03537-8 · Cited by 21
“Chronic exposure to saturated fat and hypergly-caemia leads to metabolic, oxidative, and inflammatory stress that cause β -cell exhaustion, apoptosis, and loss of β -cells mass [18, 20, 21].”
BackgroundInfluentialNanostructured Materials in Glucose Biosensing: From Fundamentals to Smart Healthcare Applications
Rajamohan, R., & Sun, S. (2025) · Biosensors · doi:10.3390/bios15100658 · Cited by 21
“Its rise is driven by urbanization, ageing, reduced physical activity, and increasing obesity [7–9].”
Varney, M. J., Steyaert, W., Coucke, P. J., Delanghe, J., Uehling, D., Joseph, B., Marcellus, R. C., Al‐awar, R., & Benovic, J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102421 · Cited by 15
“where developed insulin resistance and increased insulin demand prevents glucose mobilization and provokes pancreatic β-cell dysfunction culminating in insufficient insulin quantities and hyperglycemia (2, 3).”
BackgroundEskandari, F., Salimi, M., Binayi, F., Abdollahifar, M., Eftekhary, M., Hedayati, M., Ghanbarian, H., & Zardooz, H. (2022) · Neuroendocrinology · doi:10.1159/000526989 · Cited by 21
Anton, I. C., Mititelu-Tarțău, L., Popa, T., Poroch, M., Poroch, V., Pelin, A.-M., Pavel, L. L., Drochioi, I. C., & Botnariu, G. E. (2022) · Medicina · doi:10.3390/medicina58111620 · Cited by 18
“DM is a heterogeneous syndrome characterized by a complex disruption in regulating the energetic metabolism of the body, which affects the use of carbohydrates, fats and proteins, as well as other metabolisms [1,2].”
BackgroundPramanik, R., Dey, A., Chakrabarty, A. K., Banerjee, D., Narwaria, A., Sharma, S. K., Rai, R. K., Katiyar, C. K., & Dubey, S. K. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118402 · Cited by 18
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
“The incretin effect is responsible for 60–”
Self-citationBoudebia, O., Benamor, M. L., Bourougaa, L., Bekkar, Y., Lanez, E., Adaika, A., Bouraoui, R., Nesba, K., Chaoua, H., Hachani, S. E., et al. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00664-7 · Cited by 19
Rutkowska, M., & Olszewska, M. A. (2023) · Nutrients · doi:10.3390/nu15173756 · Cited by 20
Hamedifar, H., Mirfattahi, M., Ghomi, M. K., Azizian, H., Iraji, A., Noori, M., Moazzam, A., Dastyafteh, N., Nokhbehzaim, A., Mehrpour, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-50395-8 · Cited by 16
Noonong, K., Pranweerapaiboon, K., Chaithirayanon, K., Surayarn, K., Ditracha, P., Changklungmoa, N., Kueakhai, P., Hiransai, P., & Bunluepuech, K. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03706-x · Cited by 18
“DM is among the most prevalent diseases in the twenty-first century, mainly due to a variety of lifestyle problems [1].”
BackgroundBaniasadi, M. M., Arzhang, P., Setayesh, A., Moradi, M., Nasli‐Esfahani, E., & Azadbakht, L. (2025) · Nutrition and Diabetes · doi:10.1038/s41387-025-00386-7 · Cited by 18
“Type 2 diabetes mellitus (T2DM) represents a signi fi cant metabolic multifactorial disorder characterized by disruptions in pancreatic beta-cell function, peripheral tissue insulin resistance, and heightened pancreatic alpha-cell activity [1].”
Zhang, Z., Leng, Y., Fu, X., Yang, C., Xie, H., Yuan, H., Liang, Q., Gao, H., & Xie, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918681 · Cited by 15
“The intrinsic pathological mechanism on T2DM is an impairment in the metabolism and utilization of glucose and lipid due to insulin resistance or insufficient insulin secretion (Roden and Shulman, 2019; Reed et al., 2021).”
BackgroundPrieto-Rodríguez, J. A., Lévuok-Mena, K. P., Cardozo-Muñoz, J., Amin, J. E. P., López-Vallejo, F., Suárez, L. E. C., & Patiño-Ladino, O. J. (2022) · Plants · doi:10.3390/plants11172188 · Cited by 15
Kupai, K., Várkonyi, T. T., Török, S., Gáti, V., Czimmerer, Z., Puskás, L. G., & Szebeni, G. J. (2022) · Life · doi:10.3390/life12081205 · Cited by 19
“These changes lead to decreased glucose uptake (hyperglycemia), diminished peripheral fat uptake (dyslipidemia), compromised amino acid uptake, and higher glucagon production [33].”
BackgroundTang, L., Yang, Q., Ma, R., Zhou, P., Peng, C., Xie, C., Liang, Q., Wu, T., Gao, W., Yu, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1369968 · Cited by 24
Correlation Between Fibrinogen/Albumin and Diabetic Peripheral Neuropathy
Ban, J., Pan, X., Yang, L., Jia, Z., Zhen, R., Zhang, X., & Chen, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s427510 · Cited by 14
“Introduction Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by high blood glucose levels due to defects in insulin secretion or action.(1) Studies show that there are about 130 million people with diabetes in China, and the number of people with diabetes ranks first in the world.”
BackgroundMojica, L., Ramos-Lopez, A. S., Sánchez‐Velázquez, O. A., Gómez-Ojeda, A., & Luévano‐Contreras, C. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105927 · Cited by 15
Waghode, P., Quadir, S. S., Choudhary, D. K., Sharma, S., & Joshi, G. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01405-7 · Cited by 14
Zinc and pH modulate the ability of insulin to inhibit aggregation of islet amyloid polypeptide
McCalpin, S. D., Khemtémourian, L., Suladze, S., Ivanova, M. I., Reif, B., & Ramamoorthy, A. (2024) · Communications Biology · doi:10.1038/s42003-024-06388-y · Cited by 14
Fofack, H. M. T., Bake, M. M., Petry, S., Ateba, B. A., Onguéné, P. A., Mohammad‐Salim, H. A., Ntie‐Kang, F., Meva’à, L. M., Vakal, S., & Kenfack, C. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35191 · Cited by 15
“Furthermore, 10 % of death cases has been accounted to diabetes [3].”
BackgroundAsadi, M., Ahangari, M. M., Iraji, A., Azizian, H., Nokhbehzaim, A., Bahadorikhalili, S., Mojtabavi, S., Faramarzi, M. A., Nasli‐Esfahani, E., Larijani, B., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68176-2 · Cited by 14
Wang, Y., Yan, F., Chen, Q., Liu, F., Xu, B., Liu, Y., Huo, G., Xu, J., Li, B., & Wang, S. (2024) · Food & Function · doi:10.1039/d4fo02957g · Cited by 14
Random Oversampling-Based Diabetes Classification via Machine Learning Algorithms
Ashisha, G. R., Mary, X. A., Kanaga, E. G. M., Andrew, J., & Jennifer Eunice, R. (2024) · International Journal of Computational Intelligence Systems · doi:10.1007/s44196-024-00678-3 · Cited by 23
Enejoh, O. A., Okonkwo, C. H., Nortey, H., Kemiki, O. A., Moses, A., Mbaoji, F. N., Yusuf, A. S., & Awe, O. I. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1503593 · Cited by 15
Singh, A., Ashraf, S., Irfan, H., Venjhraj, F., Verma, A., Shaukat, A. F., Tariq, M. D., & Hamza, H. M. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002971 · Cited by 20
“Worryingly, younger populations—including children, adolescents, and adults under 30—are at increased risk of HF due to the rising prevalence of T2D and obesity [ 7 ] .”
Making sense of glucose sensors in end-stage kidney disease: A review
Williams, M. E., Steenkamp, D., & Wolpert, H. A. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.1025328 · Cited by 14
“Type 2 diabetes constitutes about 90% of all cases of diabetes, and results from tissue insulin resistance with impaired peripheral glucose uptake and dysregulated hepatic glucose production, and progressive pancreatic beta-cell dysfunction (13, 14).”
BackgroundDiabetes mellitus: Lessons from COVID-19 for monkeypox infection
Ruiz‐Pacheco, J. A., Díaz, L., Arreola-Torres, R., Fonseca-Coronado, S., & Gómez-Navarro, B. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.01.008 · Cited by 15
Al-Amily, I. M., Sjögren, M., Dunér, P., Mohammad, T., Wollheim, C. B., & Salehi, A. A. (2023) · Biomolecules · doi:10.3390/biom13030557 · Cited by 17
Yıldırım, D., Yıldız, C. Ç., Ergin, E., & Özbay, İ. (2024) · International Journal of Nursing Practice · doi:10.1111/ijn.13248 · Cited by 13
Advances in small-molecule insulin secretagogues for diabetes treatment
Su, J., Xu, J., Hu, S., Ye, H., Xie, L. N., & Ouyang, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117179 · Cited by 20
Investigating the efficacy of naphthalene-thiazole hybrid hydrazones as α-glucosidase inhibitors
Al‐Humaidi, J. Y., Abouzied, A. S., Zaki, M. E. A., Abolibda, T. Z., Alruwaili, A. H., Albedair, L. A., Mukhrish, Y. E., & Gomha, S. M. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140288 · Cited by 13
Aslam, M. W., Sabri, S., Umar, A., Khan, M. S., Abbas, M. Y., Khan, M. U., & Wajid, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151527 · Cited by 13
Tirzepatide: Clinical review of the twincretin injectable
Krauss, Z., Hintz, A., & Fisk, R. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad080 · Cited by 12
Liarakos, A. L., & Koliaki, C. C. (2023) · Biomedicines · doi:10.3390/biomedicines11071875 · Cited by 16
“The continuous rise in the number of people living with DM and especially type 2 diabetes (T2D) is tightly associated with an increased incidence of obesity on a global scale [2].”
BackgroundSeid, M. A., Diress, M., Mohammed, A., & Sinamaw, D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110905 · Cited by 13
The dual challenge of diabesity: pathophysiology, management, and future directions
Sindhwani, R., Bora, K. S., & Hazra, S. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03713-4 · Cited by 21
“The metabolic repercussions of obesity are profound, with T2DM being among the most critical outcomes (Barber 2016; Reed et al. 2021) The term “diabesity” was originally coined to emphasise the pathophysiological connection between diabetes and excess body weight (Sims et al. 1973).”
Rampadarath, A., Balogun, F. O., & Sabiu, S. (2023) · Endocrines · doi:10.3390/endocrines4020026 · Cited by 12
“Sadly, the economic burden (and deaths) accompanying the global prevalence of type-2 diabetes mellitus (T2D) particularly among the working population continues to increase [3].”
BackgroundApplication of kojic acid scaffold in the design of non‐tyrosinase enzyme inhibitors
Ashooriha, M., Ahmadi, R., Ahadi, H., & Emami, S. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14065 · Cited by 11
“However, the inconvenience of daily injections of insulin demands new small molecules for the treatment of diabetes (Reed et al., 2021; Sayem et al., 2018).”
BackgroundVizuete, A. F. K., Fróes, F. T., Seady, M., Hansen, F., Ligabue‐Braun, R., Gonçalves, C., & Souza, D. O. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03774-1 · Cited by 12
Aksoy, A., Abayomi, J. C., Relph, N., & Butler, T. (2024) · Obesity Reviews · doi:10.1111/obr.13733 · Cited by 14
Sarkar, K., Chatterjee, A., Bankura, B., Bank, S., Paul, N., Chatterjee, S., Das, A., Dutta, K., Chakraborty, S., De, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307166 · Cited by 18
Nxumalo, M. B., Ntanzi, N., Kumalo, H. M., & Khan, R. B. (2024) · Nutrients · doi:10.3390/nu16203496 · Cited by 15
“According to a recent study [5], diabetes held the position of the second-most common cause of death in South Africa in 2016 and 2017, while it was the leading cause of death among females.”
BackgroundInfluential(2022) · Biointerface Research in Applied Chemistry · doi:10.33263/briac133.228 · Cited by 11
Influence of metformin intake on serum vitamin B12 levels in patients with type 2 diabetes mellitus
Al‐Fawaeir, S., & Al‐Odat, I. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279740 · Cited by 12
Zhang, H., Yu, L., & Yun, G. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s394099 · Cited by 14
“Introduction One of the most common and severe public health issues in the 21st century is type 2 diabetes mellitus (T2DM).(1) Over 90% of local individuals with diabetes mellitus are T2DM patients, the most prevalent type of disease in China.”
BackgroundUnravelling the role of natural herbs for the management of diabetes mellitus
Firdous, S. M., Irfan, Z., Giri, S., & Asaba, N. S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01904-4 · Cited by 14
“Improved glucose uptake and glucose homeostasis are supported by increased GLUT-4 activity [177, 178].”
Sangali, P., Abdullahi, S., Nosrati, M., Khosravi-Asrami, O. F., Mahrooz, A., & Bagheri, A. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01391-w · Cited by 12
Damarov, I. S., Korbolina, E. E., RYKOVA, E. Y., & Merkulova, T. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179297 · Cited by 14
“Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and one of the most prevalent metabolic disorders, which affects hundreds of millions of individuals worldwide [1].”
BackgroundStefano, E. D., Hüttmann, N., Dekker, P. M., Tomassen, M. M. M., Oliviero, T., Fogliano, V., & Udenigwe, C. C. (2024) · Food & Function · doi:10.1039/d4fo03326d · Cited by 10
Green, C., Zaman, V., Blumenstock, K., Banik, N. L., & Haque, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010132 · Cited by 13
“The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) states that T2DM is a condition in which the pancreas does not make enough insulin to help glucose reach cells in the body, and this causes the blood glucose or blood sugar level to be extremely high [32,33].”
Trașcă, D.-M., Dop, D., Stoica, G. A., Niculescu, Ș. A., Carmen, N. E., Văruț, R. M., & Singer, C. E. (2025) · Pharmaceuticals · doi:10.3390/ph18071035 · Cited by 12
“Projections once estimated >360 million global cases by 2030 [42].”
Rosa, I., Lages, M., Grilo, C., Barros, R., & Guarino, M. P. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.862065 · Cited by 13
“that more than 600 million people will be diagnosed with T2DM, and around the same number of people will develop impaired glucose tolerance, a state that frequently precedes T2DM (2).”
BackgroundInfluentialDiet Quality, Microbial Lignan Metabolites, and Cardiometabolic Health among US Adults
Koemel, N. A., Senior, A. M., Benmarhnia, T., Holmes, A. J., Okada, M., Oulhote, Y., Parker, H. M., Shah, S., Simpson, S. J., Raubenheimer, D., et al. (2023) · Nutrients · doi:10.3390/nu15061412 · Cited by 12
Metadata
- Authors
- Reed, J., Bain, S., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Reed, Josh
- Bain, Stephen
- Kanamarlapudi, Venkateswarlu
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- Volume 14
- Pages
- 3567-3602
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8369920
- OpenAlex
- W3191601669
- Cited by
- 441
- References
- 326
- Citations by year
- 2026: 73 · 2025: 109 · 2024: 107 · 2023: 98 · 2022: 51 · 2021: 2
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Directorate for Biological Sciences
- Medical Research Council (G0401232)
- Biotechnology and Biological Sciences Research Council (BB/S019588/1, BB/F017596/1, BB/C515455/2, 1095087)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes epidemiology, diabetes aetiology, diabetes pathogenesis, impaired insulin secretion, glucagon-like peptide-1, incretins, GLP-1 receptor agonists, bariatric surgery alternatives, weight loss, diabetes complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.